Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
Serina Therapeutics (NYSE: SER) announced that their Chief Development Officer, Dr. Randall Moreadith, will present groundbreaking data at the ACS Spring 2025 Meeting in San Diego. The presentation, focusing on their POZ Platform™ drug delivery technology, will showcase findings on their proprietary POZ-lipid technology used in lipid nanoparticles (LNPs).
Key research findings demonstrate that Serina's POZ-lipid showed no IgM or IgG antibody response in rats after repeated dosing, unlike conventional polyethylene glycol (PEG)-lipids which triggered strong antibody responses. This is particularly significant as anti-PEG antibodies have been linked to anaphylaxis and serious adverse events in patients receiving PEGylated mRNA vaccines.
This breakthrough discovery suggests potential for developing safer and more effective LNP formulations for gene therapy and RNA-based medicines.
Serina Therapeutics (NYSE: SER) ha annunciato che il loro Chief Development Officer, il Dr. Randall Moreadith, presenterà dati innovativi al Meeting Primaverile ACS 2025 a San Diego. La presentazione, incentrata sulla loro tecnologia di somministrazione dei farmaci POZ Platform™, mostrerà risultati sulla loro tecnologia proprietaria POZ-lipid utilizzata nei nanoparticelle lipidiche (LNP).
I principali risultati della ricerca dimostrano che il POZ-lipid di Serina non ha mostrato risposta anticorpale IgM o IgG nei ratti dopo dosaggi ripetuti, a differenza dei lipidi convenzionali a base di polietilene glicole (PEG) che hanno innescato forti risposte anticorpali. Questo è particolarmente significativo poiché gli anticorpi anti-PEG sono stati collegati ad anafilassi e gravi eventi avversi nei pazienti che ricevono vaccini mRNA PEGilati.
Questa scoperta rivoluzionaria suggerisce un potenziale per sviluppare formulazioni LNP più sicure ed efficaci per la terapia genica e i farmaci basati su RNA.
Serina Therapeutics (NYSE: SER) anunció que su Director de Desarrollo, el Dr. Randall Moreadith, presentará datos innovadores en la Reunión de Primavera ACS 2025 en San Diego. La presentación, centrada en su tecnología de entrega de medicamentos POZ Platform™, mostrará hallazgos sobre su tecnología patentada POZ-lipid utilizada en nanopartículas lipídicas (LNP).
Los hallazgos clave de la investigación demuestran que el POZ-lipid de Serina no mostró respuesta de anticuerpos IgM o IgG en ratas tras dosis repetidas, a diferencia de los lipídicos convencionales de polietilenglicol (PEG) que provocaron fuertes respuestas de anticuerpos. Esto es particularmente significativo, ya que los anticuerpos anti-PEG se han relacionado con anafilaxis y eventos adversos graves en pacientes que reciben vacunas de ARNm PEGiladas.
Este descubrimiento innovador sugiere un potencial para desarrollar formulaciones LNP más seguras y efectivas para la terapia génica y medicamentos basados en ARN.
세리나 테라퓨틱스 (NYSE: SER)는 그들의 최고 개발 책임자인 랜달 모레디스 박사가 샌디에고에서 열리는 2025년 ACS 봄 회의에서 혁신적인 데이터를 발표할 것이라고 발표했습니다. 발표는 그들의 POZ 플랫폼™ 약물 전달 기술에 초점을 맞추며, 지질 나노입자(LNP)에 사용되는 독점 POZ-지질 기술에 대한 결과를 보여줄 것입니다.
주요 연구 결과는 세리나의 POZ-지질이 반복 투여 후 쥐에서 IgM 또는 IgG 항체 반응이 없었다는 것을 보여줍니다. 이는 강한 항체 반응을 유발한 일반적인 폴리에틸렌 글리콜(PEG) 지질과는 다릅니다. 이는 PEG 항체가 PEG화된 mRNA 백신을 받는 환자에서 아나필락시스 및 심각한 부작용과 관련이 있다는 점에서 특히 중요합니다.
이 혁신적인 발견은 유전자 치료 및 RNA 기반 의약품을 위한 더 안전하고 효과적인 LNP 제형 개발의 가능성을 제시합니다.
Serina Therapeutics (NYSE: SER) a annoncé que son directeur du développement, le Dr Randall Moreadith, présentera des données révolutionnaires lors de la Réunion de Printemps ACS 2025 à San Diego. La présentation, axée sur leur technologie de délivrance de médicaments POZ Platform™, mettra en avant des résultats sur leur technologie propriétaire POZ-lipid utilisée dans les nanoparticules lipidiques (LNP).
Les principales découvertes de la recherche montrent que le POZ-lipid de Serina n'a montré aucune réponse d'anticorps IgM ou IgG chez les rats après des doses répétées, contrairement aux lipides conventionnels à base de polyéthylène glycol (PEG) qui ont déclenché de fortes réponses d'anticorps. Cela est particulièrement significatif car les anticorps anti-PEG ont été liés à des anaphylaxies et à des événements indésirables graves chez les patients recevant des vaccins à ARNm PEGylés.
Cette découverte révolutionnaire suggère un potentiel pour développer des formulations LNP plus sûres et plus efficaces pour la thérapie génique et les médicaments à base d'ARN.
Serina Therapeutics (NYSE: SER) gab bekannt, dass ihr Chief Development Officer, Dr. Randall Moreadith, bahnbrechende Daten auf dem ACS Frühjahrsmeeting 2025 in San Diego präsentieren wird. Die Präsentation, die sich auf ihre POZ Platform™ Arzneimittelabgabetechnologie konzentriert, wird Ergebnisse zu ihrer proprietären POZ-Lipid-Technologie zeigen, die in lipidischen Nanopartikeln (LNPs) verwendet wird.
Wichtige Forschungsergebnisse zeigen, dass Serinas POZ-Lipid keine IgM- oder IgG-Antikörperreaktion bei Ratten nach wiederholter Dosierung zeigte, im Gegensatz zu konventionellen Polyethylenglykol (PEG)-Lipiden, die starke Antikörperreaktionen auslösten. Dies ist besonders bedeutsam, da anti-PEG-Antikörper mit Anaphylaxie und schweren unerwünschten Ereignissen bei Patienten in Verbindung gebracht wurden, die PEGylierte mRNA-Impfstoffe erhalten haben.
Diese bahnbrechende Entdeckung deutet auf das Potenzial hin, sicherere und effektivere LNP-Formulierungen für Gentherapie und RNA-basierte Medikamente zu entwickeln.
- None.
- None.
HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will highlight findings on the immunogenic profile of Serina’s proprietary POZ-lipid technology.
Dr. Moreadith will share data demonstrating that Serina’s POZ-lipid, a key component of lipid nanoparticles (LNPs), did not trigger an IgM or IgG antibody response following repeat dosing in rats. In contrast, polyethylene glycol (PEG)-lipid standards, commonly used in current LNP formulations, elicited a strong and boosted antibody response.
Anti-PEG antibodies have been implicated as a potential cause of anaphylaxis and other serious adverse events observed in humans receiving PEGylated mRNA vaccines, such as those from Pfizer and Moderna. The absence of an immune response to Serina’s POZ-lipid represents a novel discovery that could enable the development of safer and more effective LNP formulations for gene therapy and RNA-based medicines.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina’s Annual Report on Form 10-K, and Serina’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
What breakthrough did Serina Therapeutics (SER) announce for their POZ-lipid technology in March 2025?
How does Serina's (SER) POZ-lipid technology differ from current PEG-lipid standards?
What are the potential advantages of Serina's (SER) POZ Platform technology for mRNA vaccines?
When and where will Serina Therapeutics (SER) present their POZ-lipid research findings?
What clinical implications does Serina's (SER) POZ-lipid discovery have for gene therapy?
